TY - JOUR
TI - Attainment of Inactive Disease Following Discontinuation of Adalimumab Monotherapy in Patients with Enthesitis-Related Arthritis: A Real-Life, Dual-Center Experience
AU - Papailiou, S.
AU - Dasoula, F.
AU - Tsolia, M.N.
AU - Maritsi, D.N.
JO - JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
PY - 2022
VL - 28
TODO - 2
SP - E616-E618
PB - Lippincott Williams and Wilkins
SN - null
TODO - 10.1097/RHU.0000000000001762
TODO - adalimumab;  antirheumatic agent, human;  juvenile rheumatoid arthritis;  treatment outcome, Adalimumab;  Antirheumatic Agents;  Arthritis, Juvenile;  Humans;  Treatment Outcome
TODO - The optimum duration of treatment in patients with juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis (ERA), is an area of pivotal concern for both parents and physicians. Novel medicines have managed to achieve remission of this otherwise debilitating condition1; however, issues regarding the duration and the best timing for termination of therapy endure.2 Enthesitis-related arthritis remains one of the most challenging JIA subtypes in terms of drug management and withdrawal. We report the results of a medical records review study aiming to describe the long-term outcome of children with a specific subcategory of ERA, solely treated with a tumor necrosis factor inhibitor (TNFi) (adalimumab [ADA]), in whom treatment was discontinued, following sustained clinical remission, and to identify potential relapse-associated risk factors. © 2022 Lippincott Williams and Wilkins. All rights reserved.
ER -